Gut Metabolite TMAO Predicts Aortic Aneurysm Growth and Surgery Risk
Elevated blood TMAO levels nearly triple the risk of fast-growing aortic aneurysms, offering a new biomarker for surgical timing decisions.
Summary
A gut microbiome-derived metabolite called TMAO (trimethylamine N-oxide) may help predict which patients with abdominal aortic aneurysms (AAA) will experience rapid growth and need surgery. Researchers measured blood TMAO in 895 patients across two independent cohorts — one in Sweden, one in the US — and tracked aneurysm size over time. Patients with elevated TMAO (≥6.2 µM) were roughly 2.3 to 2.75 times more likely to have fast-growing aneurysms and about 2.4 to 2.7 times more likely to be recommended for surgical repair. These findings were consistent across both cohorts and held up after adjusting for traditional cardiovascular risk factors, suggesting TMAO could become a clinically useful blood test to guide AAA surveillance and intervention timing.
Detailed Summary
Abdominal aortic aneurysm (AAA) is a potentially fatal condition in which the aorta's lower segment balloons outward — rupture carries an out-of-hospital mortality rate of 70–80%. Currently, clinicians rely primarily on aneurysm diameter and crude growth rate thresholds to decide when to recommend surgical repair, but no validated blood biomarker exists to help risk-stratify patients. This study investigates whether circulating levels of the gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) can predict who will experience fast aneurysm growth or require surgical intervention.
The researchers drew on two prospective cohort studies: a European Discovery Cohort (n=237, Uppsala, Sweden, recruited 2008–2016) and a US Replication Cohort (n=658, Cleveland Clinic, recruited 2019–2022). TMAO was measured using gold-standard stable-isotope-dilution liquid chromatography-tandem mass spectrometry. The key outcomes were fast-growing AAA (≥4.0 mm/year) and recommended surgical intervention (diameter ≥5.5 cm or growth ≥4.0 mm/year). The pre-specified high-TMAO cutoff of ≥6.2 µM corresponds to the 75th percentile in prior large cardiovascular event cohorts.
In the European Cohort, elevated TMAO was independently associated with AAA presence, fast-growing AAA (adjusted OR 2.75; 95% CI 1.20–6.79), and recommended surgical intervention (aOR 2.67; 95% CI 1.24–6.09), after adjustment for age, sex, smoking, hypertension, diabetes, dyslipidemia, and renal function. Importantly, these associations were replicated in the US Cohort: fast-growing AAA (aOR 2.71; 95% CI 1.53–4.80) and recommended surgical intervention (aOR 2.73; 95% CI 1.56–4.80). In the combined cohort (n=895), aORs were 2.30 (95% CI 1.47–3.62) for fast-growing AAA and 2.41 (95% CI 1.55–3.74) for recommended surgical intervention.
Beyond odds ratios, adding TMAO to models containing traditional cardiovascular risk factors significantly improved risk discrimination for both fast-growing AAA and surgical recommendation endpoints. This incremental predictive value is clinically meaningful — it suggests TMAO captures a distinct biological pathway not reflected by conventional risk scores. The mechanism likely involves gut microbial conversion of dietary nutrients (choline, L-carnitine) into TMA, which is then oxidized to TMAO in the liver, promoting vascular inflammation and aortic wall remodeling.
The study also draws on prior animal model work from the same group showing that pharmacological suppression of gut microbial TMAO production halted AAA progression in multiple mouse models, and that TMAO supplementation reversed this protective effect — establishing a causal rather than merely associative relationship. Together, the animal and human data position TMAO as both a biomarker and a potential therapeutic target. Key caveats include observational design, single-center cohorts, predominantly male and Caucasian European participants, and non-fasting blood draws, which may introduce variability in TMAO measurements. Nonetheless, the cross-cohort replication substantially strengthens confidence in these findings.
Key Findings
- Elevated TMAO (≥6.2 µM) associated with fast-growing AAA in European Cohort: adjusted OR 2.75 (95% CI 1.20–6.79)
- Elevated TMAO associated with recommended surgical intervention in European Cohort: adjusted OR 2.67 (95% CI 1.24–6.09)
- Findings replicated in US Cohort: fast-growing AAA aOR 2.71 (95% CI 1.53–4.80); surgical intervention aOR 2.73 (95% CI 1.56–4.80)
- Combined cohort (n=895) confirmed elevated TMAO risk for fast-growing AAA: aOR 2.30 (95% CI 1.47–3.62)
- Adding TMAO to traditional risk factor models significantly improved risk discrimination for both fast-growing AAA and surgical intervention endpoints
- Associations remained significant after adjusting for renal function (eGFR), addressing the confound that kidney disease elevates TMAO independently
- TMAO cutoff of ≥6.2 µM corresponds to 75th percentile in prior large CVD event cohorts, providing a clinically actionable threshold
Methodology
Two independent prospective cohort studies: a European Discovery Cohort (n=237, Uppsala, Sweden) and a US Replication Cohort (n=658, Cleveland Clinic), totaling 895 participants undergoing serial aortic imaging surveillance. TMAO was quantified by stable-isotope-dilution LC-MS/MS from baseline plasma samples. Multivariable logistic regression adjusted for age, sex, smoking, hypertension, diabetes, dyslipidemia, and eGFR; model improvement was assessed by comparing base models with and without TMAO, with cross-validation performed across both cohorts.
Study Limitations
The study is observational and cannot establish causality in humans, and both cohorts are single-center with predominantly male, Caucasian populations, limiting generalizability. Blood draws were not necessarily fasting, which can cause variability in TMAO levels. Several study authors have financial interests related to TMAO research, including patents and royalties, representing potential conflicts of interest that readers should consider.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.